ArticleInternational clinical psychopharmacology2014
Pharmacokinetics of olanzapine long-acting injection: the clinical perspective.
Article in International clinical psychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 47 citations in OpenAlex.
- Diffusion dimensionality modeling of subcutaneous/intramuscular absorption of antibodies and long-acting injectables.Journal of pharmacokinetics and pharmacodynamics · 2025Article
- Novel and Emerging Treatments for Agitation in Schizophrenia and Bipolar Disorder.Healthcare (Basel, Switzerland) · 2025Review
- Membrane Permeability Monitoring to Antipsychotic Olanzapine Using Platinum Black-Modified Electrodes.Sensors (Basel, Switzerland) · 2025Article
- Comparative modelling of foetal exposure to maternal long-acting injectable versus oral daily antipsychotics.npj women's health · 2025Article
- Ultra-Long-Term Delivery of Hydrophilic Drugs Using InjectablebioRxiv : the preprint server for biology · 2024Article
- Acute Urinary Retention Associated with Olanzapine Long-acting Injection: A Case Report.Indian journal of psychological medicine · 2024Article
- Long-Acting Injectable Antipsychotics-A Review on Formulation and In Vitro Dissolution.Pharmaceutics · 2023Review
- Association of smoking cigarettes, age, and sex with serum concentrations of olanzapine in patients with schizophrenia.Biochemia medica · 2023Article
- Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal.Drug, healthcare and patient safety · 2023Review
- Olanzapine Pharmacokinetics: A Clinical Review of Current Insights and Remaining Questions.Pharmacogenomics and personalized medicine · 2023Review
- The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?International clinical psychopharmacology · 2022Review
- Post-Injection Delirium/Sedation Syndrome: A Case Report and 2-Year Follow-Up.The American journal of case reports · 2022Article
- Postinjection delirium/sedation syndrome in a transgender man undergoing hormone therapy.The mental health clinician · 2022Article
- Modeling Complex Pharmacokinetics of Long-Acting Injectable Products Using Convolution-Based Models With Nonparametric Input Functions.Journal of clinical pharmacology · 2021Article
- Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview.CNS drugs · 2021Review
- Long-Acting Injectable Antipsychotics: Analysis of Prescription Patterns and Patient Characteristics in Mental Health from a Spanish Real-World Study.Clinical drug investigation · 2020Article
- Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation.Neuropsychiatric disease and treatment · 2019Article
- Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia.Journal of clinical psychopharmacology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Olanzapine long-acting injection (OLAI) is a sustained-release depot antipsychotic for the treatment of schizophrenia in adults. Our objective was to explain the pharmacokinetics of OLAI to provide clinical insight. Simulation models and data from clinical trials are presented. Olanzapine concentrations were observed immediately upon injection. Half-life was ∼30 days, controlled by the slow rate of intramuscular absorption rather than the 30-h elimination rate-based half-life of oral olanzapine. As each injection builds on the drug still being released from previous injections, concentrations increase gradually until a steady state is reached after ∼3 months. Concentrations were similar to oral olanzapine and proportional to the dose; the average steady-state concentrations (10th-90th percentile) for the 150, 210, and 300 mg/2-week doses were 16-32, 15-55, and 20-67 ng/ml, respectively, and those for the 300 and 405 mg/4-week doses were 19-48 and 19-62 ng/ml, respectively. Peak concentrations most often occurred at 2-4 days after injection. Peak-to-trough fluctuation was greater for the 4-week dosing interval than the 2-week one, with no apparent clinical ramifications for these differences. Trough concentrations were above the lower end of the therapeutic range, even at the first injection. Long-term use up to 6 years indicated no additional accumulation. The impact of smoking and sex was similar, but less pronounced than for oral olanzapine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.